The use of bispecific antibodies (BsAb) prior to CAR-T cell therapy has been shown to be a more optimal sequence in patients with relapsed or refractory large B-cell lymphoma (LBCL) compared with BsAb after CAR-T.[1] A real-world study of 85 patients after CAR-T failure showed a median progression-free survival (mPFS) of 3.27 months and a median overall survival (mOS) of 6.83 months.2 The mPFS was significantly better with immediate BsAb administration (4.37 months) vs. later (2.48 months, p=0.026), while the mOS did not differ (7.73 vs. 5.10 months, p=0.100).2 CD20×CD3 bispecific antibodies such as mosunetuzumab, glofitamab, odronextamab and epcoritamab achieved complete responses ranging from 22% to 46% in patients with LBCL after CAR-T.[1] BsAbs show antitumor activity and a manageable safety profile in the real world after CAR-T failure.The optimal sequence of BsAbs and CAR-T requires further prospective studies with longer follow-up[2].